Taste-masking of efavirenz through microencapsulation
dc.contributor.advisor | Aucamp, Marique Elizabeth | |
dc.contributor.author | Nel, Marise | |
dc.date.accessioned | 2022-03-17T07:29:01Z | |
dc.date.accessioned | 2024-05-15T07:42:46Z | |
dc.date.available | 2022-03-17T07:29:01Z | |
dc.date.available | 2024-05-15T07:42:46Z | |
dc.date.issued | 2021 | |
dc.description | Magister Pharmaceuticae - MPharm | en_US |
dc.description.abstract | It is a well-known fact that a significant gap exists in the development of child-friendly dosage forms, detrimentally affecting paediatric patient compliance, especially in the treatment of debilitating diseases such as human-immunodeficiency virus (HIV) infection. Although not recommended as first-line treatment, efavirenz (EFV) still forms part of the South African Department of Health’s treatment regimen for HIV-infected children. EFV is however an extremely bitter-tasting drug, known to cause “burning-mouth” syndrome and therefore paediatric patient compliance related to EFV dosage forms has generally proven low partly due to poor palatability. A multitude of taste-masking strategies may be applied in an effort to alleviate this factor. One of these strategies, which is well-known and more widely applied in food sciences than in pharmaceutical sciences, is that of compound microencapsulation through spray-drying and ionic gelation. In this study the potential of utilizing EFV-loaded microcapsules obtained via spray-drying and EFV-loaded calcium-alginate beads obtained via ionic gelation as possible taste-masking strategies were investigated. | en_US |
dc.identifier.uri | https://hdl.handle.net/10566/15135 | |
dc.language.iso | en | en_US |
dc.publisher | University of the Western Cape | en_US |
dc.rights.holder | University of the Western Cape | en_US |
dc.subject | Paediatric drug development | en_US |
dc.subject | Taste-masking | en_US |
dc.subject | Spray-drying | en_US |
dc.subject | Ionic gelation | en_US |
dc.subject | HIV infection | en_US |
dc.title | Taste-masking of efavirenz through microencapsulation | en_US |